Loading
Loading
Research Overview
Recombinant GLP-2 analogue; activates GLP-2 receptors on intestinal subepithelial myofibroblasts and enteroendocrine cells to promote villus hypertrophy, crypt depth, and mucosal surface area in remaining small bowel, improving nutrient absorption in short bowel syndrome.
GLP-2 (glucagon-like peptide 2) is co-encoded with GLP-1 in the proglucagon gene but has entirely different biological effects: where GLP-1 regulates appetite and insulin secretion, GLP-2 promotes intestinal epithelial growth, increases villus height, deepens crypts, and enhances nutrient absorption capacity. Teduglutide is a recombinant GLP-2 analogue with a proline substitution that extends its half-life from approximately 7 minutes (native GLP-2) to approximately 2 hours.
Short bowel syndrome (SBS) with intestinal failure results from surgical resection of significant lengths of small bowel (trauma, Crohn's disease, mesenteric ischaemia, necrotising enterocolitis) leaving insufficient absorptive surface for adequate nutrition absorption. Patients require parenteral nutrition (IV feeding) to survive. Teduglutide promotes the remaining bowel to hypertrophy and absorb more efficiently, enabling reduction or elimination of parenteral nutrition dependence.
Clinical trials demonstrated that teduglutide treatment reduced parenteral nutrition requirements by approximately 4.4 hours per week versus placebo in SBS-IF patients, with approximately 63% of teduglutide patients achieving clinically meaningful PN reduction. This makes it one of the very few pharmaceutical agents that can modify the course of intestinal failure rather than merely managing its consequences.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, teduglutide (gattex / revestive) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Teduglutide (Gattex / Revestive) research is most relevant to protocols examining:
Short bowel syndrome and intestinal adaptation research
GLP-2 receptor pathway and intestinal mucosa studies
Villus hypertrophy and crypt depth mechanism investigations
Researchers studying intestinal failure parenteral nutrition weaning
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~2 hours). Review data, confirm baseline recovery before any repeat protocol.
Recombinant GLP-2 analogue; activates GLP-2 receptors on intestinal subepithelial myofibroblasts and enteroendocrine cells to promote villus hypertrophy, crypt depth, and mucosal surface area in remaining small bowel, improving nutrient absorption in short bowel syndrome.
| Parameter | Value |
|---|---|
| Dose range | 0.05 mg/kg/day subcutaneous |
| Schedule | Once daily |
| Route | Subcutaneous |
| Half-life | ~2 hours |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.